Cortexin vs Cerebrolysin

Overview

Cortexin and Cerebrolysin are both brain-derived peptide preparations used in Russia and Eastern Europe for various neurological conditions. Cerebrolysin is derived from pig brain, while Cortexin is derived from cattle cerebral cortex. Neither is FDA-approved, and Western evidence is limited.

Key Facts

Aspect	Cortexin	Cerebrolysin
Source	Bovine cerebral cortex	Porcine brain
Composition	Peptide mixture	Peptide mixture
Type	Complex biological	Complex biological
Approval	Russia	Russia, Europe (some)
FDA Status	Not approved	Not approved

Composition Comparison

Component	Cortexin	Cerebrolysin
Peptide Content	Low-molecular-weight peptides	~25% peptides, amino acids
Source Tissue	Cerebral cortex (cattle)	Whole brain (pig)
Active Components	Poorly characterized	Contains BDNF, CNTF, others
Standardization	Limited	Some characterization

What Are These Preparations?

Both are:

• Extracts from animal brain tissue
• Complex mixtures of peptides and amino acids
• Not single defined molecules
• Difficult to fully characterize
• Used historically in Eastern Europe

Mechanism (Proposed)

Mechanism	Cortexin	Cerebrolysin
Neurotrophic Support	Claimed	Claimed
Antioxidant	Claimed	Claimed
Neuroprotection	Claimed	Claimed, some evidence
Specific Targets	Not defined	BDNF-like activity

Evidence Comparison

Aspect	Cortexin	Cerebrolysin
Human Trials	Russian studies	Multiple (including Western)
Cochrane Reviews	Not reviewed	Mixed conclusions
Western Publications	Very few	More extensive
Quality of Evidence	Low	Low-Moderate

Cerebrolysin Evidence

Cerebrolysin has more Western research:

• Stroke trials (mixed results)
• Alzheimer’s trials (modest effects)
• TBI studies (some positive signals)
• Cochrane reviews: insufficient evidence

Cortexin Evidence

Cortexin has less international research:

• Primarily Russian publications
• Pediatric neurological conditions
• Stroke recovery
• Lower publication standards often

Clinical Applications (Where Approved)

Cortexin Uses (Russia)

Indication	Evidence
Pediatric neurology	Russian data
Stroke recovery	Russian data
TBI	Russian data
Cognitive impairment	Russian data

Cerebrolysin Uses

Indication	Evidence
Stroke	Multiple trials, mixed
Alzheimer’s disease	Some trials
TBI	Some positive data
Dementia	Limited

Administration

Aspect	Cortexin	Cerebrolysin
Route	IM (intramuscular)	IV or IM
Course Duration	10-20 days	10-30 days

Safety Profile

Cortexin

Aspect	Information
Common Effects	Injection site reactions
Serious Concerns	Prion disease (theoretical - bovine)
Drug Interactions	Not well characterized
Long-term Safety	Not established

Cerebrolysin

Aspect	Information
Common Effects	Injection site, dizziness
Serious Concerns	Prion disease (theoretical - porcine)
Drug Interactions	Some data
Long-term Safety	More data than Cortexin

Prion Disease Concern

Both are animal brain-derived:

• Theoretical risk of prion transmission
• Manufacturing processes claim to eliminate risk
• No documented cases linked to these products
• Regulatory bodies in some countries accept safety

Regulatory Status

Aspect	Cortexin	Cerebrolysin
Russia	Approved	Approved
EU	Not approved	Some countries
US (FDA)	Not approved	Not approved
Manufacturing	Russia	Austria (EVER Pharma)

Quality Considerations

Factor	Cortexin	Cerebrolysin
Manufacturer	Russian	Austrian/Western
GMP Standards	Russian GMP	EU GMP
Batch Consistency	Variable	More standardized
International Access	Limited	More available

Key Differences

Factor	Cortexin	Cerebrolysin
Source	Bovine cortex	Porcine brain
Research Base	Russian primarily	More international
Manufacturing	Russian	Western
Quality Control	Lower	Higher
Western Evidence	Minimal	Some
Administration	IM only	IV or IM

Summary

• Both are brain-derived peptide preparations with limited Western evidence
• Cerebrolysin has more international research and Western manufacturing standards
• Cortexin is primarily researched/manufactured in Russia with less international data
• Neither is FDA-approved; evidence remains insufficient by Western standards
• Theoretical prion concerns exist for both (animal brain-derived)
• Cerebrolysin has been more extensively evaluated in Western trials (though results are mixed)
• Quality and standardization favor Cerebrolysin

---

This comparison is for educational purposes only. Neither preparation is FDA-approved. Evidence from Western clinical trials remains insufficient for most claimed indications. Consult a healthcare provider for medical decisions.